LAUSR

Simple Summary Due to the late onset of symptoms and aggressive growth, cholangiocellular carcinomas (CCA) are associated with poor outcome. In advanced stages, interventional therapies and systemic therapies are particularly used. The combination of locoregional therapeutic approaches with modern system therapies represents a promising approach to improve the outcome for cholangiocellular carcinoma patients. Abstract Locoregional therapy options for CCA are used, in particular, for non-resectable tumors and aim to reduce tumor viability or delay tumor growth and ultimately prolong overall survival. In addition to local ablative procedures such as radiofrequency- or microwave-ablation, transarterial procedures such as transarterial embolization (TAE), transarterial chemoembolization (TACE), or selective internal radiotherapy (SIRT) play a major role. In particular, in combination with advances in molecular medicine and immunotherapy, there has been a further development in the therapy of primary malignant liver tumors in recent years. In this review, we analyze data from recent studies and examine the implications for therapy of CCA, particularly with regard to the combination of locoregional therapies with modern systemic therapies.